Literature DB >> 22202003

Molecular recognition theory and sense-antisense interaction: therapeutic applications in autoimmunity.

Matthew Thomas Hardison1, James Edwin Blalock.   

Abstract

Perhaps behind only the understanding of the genetic code in importance is the comprehension of protein sequence and structure in its effect on modern scientific investigation. How proteins are structured and interact dictates a considerable amount of the body's processes in maintaining homeostasis. Unfortunately, in diseases of autoimmunity, these processes are directed against the body itself and most of the current clinical responses are severely lacking. This review addresses current therapeutics involved in the treatment of various autoimmune diseases and details potential future therapeutics designed with a more targeted approach. Detailed in this manuscript is the concept of utilizing peptides possessing an inverse hydropathy to the immunogenic region of proteins to generate anti-idiotypic (anti-Id) and anti-clonotypic T cell receptor (TCR) antibodies (Abs). Theoretically, the anti-Id Abs cross react with Id Abs and negate the powerful machinery of the adaptive immune response with little to no side effects. A series of studies by a number of groups have shown this to be an exciting and intriguing concept that will likely play a role in the future treatment of autoimmune diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22202003      PMCID: PMC4107873          DOI: 10.2741/e508

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  66 in total

1.  Generation of idiotypic and anti-idiotypic antibodies by immunization with peptides encoded by complementary RNA: a possible molecular basis for the network theory.

Authors:  L R Smith; K L Bost; J E Blalock
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

2.  The peptides APLHK, EHIPA and GAPL are hydropathically equivalent peptide mimics of a fibrinogen binding domain of glycoprotein IIb/IIIa.

Authors:  T K Gartner; R Loudon; D B Taylor
Journal:  Biochem Biophys Res Commun       Date:  1991-11-14       Impact factor: 3.575

3.  Recognition properties of peptides hydropathically complementary to residues 356-375 of the c-raf protein.

Authors:  G Fassina; P P Roller; A D Olson; S S Thorgeirsson; J G Omichinski
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

4.  Active immunization with complementary peptide PBM 9-1: preliminary evidence that it modulates experimental allergic encephalomyelitis in PL/J mice and Lewis rats.

Authors:  S R Zhou; J N Whitaker
Journal:  J Neurosci Res       Date:  1996-08-15       Impact factor: 4.164

5.  The use of complementary peptides in the purification of an angiotensin II binding protein.

Authors:  T S Elton; S Oparil; J E Blalock
Journal:  J Hypertens Suppl       Date:  1988-12

6.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

Review 7.  Determinant spreading: lessons from animal models and human disease.

Authors:  J McCluskey; A D Farris; C L Keech; A W Purcell; M Rischmueller; G Kinoshita; P Reynolds; T P Gordon
Journal:  Immunol Rev       Date:  1998-08       Impact factor: 12.988

8.  A novel arginine vasopressin-binding peptide that blocks arginine vasopressin modulation of immune function.

Authors:  H M Johnson; B A Torres
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

9.  Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA.

Authors:  T S Elton; L D Dion; K L Bost; S Oparil; J E Blalock
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.

Authors:  William F Pendergraft; Gloria A Preston; Ruchir R Shah; Alexander Tropsha; Charles W Carter; J Charles Jennette; Ronald J Falk
Journal:  Nat Med       Date:  2003-12-07       Impact factor: 87.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.